# data[].attributes.body
https://padlet.com/sabrinadietrich1/gh73ipg8hgj55cbq

# data[].attributes.headline
Questions for group work & plenary discussion

# data[].attributes.subject
Questions for group work & plenary discussion

# data[].attributes.body
Eline Aas, University of Oslo

# data[].attributes.attachment_link.readable_text
My research is related to economic evaluation of new interventions, both alongside clinical trials and Health Technology Assessments. In addition I work with end-of-life care, precision medicine, register data, health behavior, inequalities in health and screening.

Projects - PI:

PRECISE - A health economic approach to evaluate uncertain evidence in personalised medicine (Nordforsk)

SAFE (Securing High-Quality Care for Cancer Patients at their End-of-Life)

Screening in a Health Economics Perspective.

HEVAL5120 - Modeling in Economic Evaluation I

HEVAL5130 - Modeling in Economic Evaluation II

Publications
View all works in Cristin View all works in Cristin View all works in Cristin

# data[].attributes.attachment_link.title
Eline Aas - Institute of Health and Society

# data[].attributes.attachment_link.description
My research is related to economic evaluation of new interventions, both alongside clinical trials and Health Technology Assessments. In addition I work with end-of-life care, precision medicine, register data, health behavior, inequalities in health and screening.

# data[].attributes.body
Margreet Franken, Erasmus University Rotterdam

# data[].attributes.attachment_link.readable_text
(external) researcher Erasmus School of Health Policy & Management Health Technology Assessment (HTA)

Profile

Margreet Franken, PhD is a senior researcher at the institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands. She obtained a Bachelor degree in Nursing (1992), after which she specialised in coronary (1995) and intensive care nursing (1998). From 1992 until 2008 she worked as a quality care manager, clinical nurse educator, and specialised coronary and intensive care nurse in hospitals in Arnhem, Rotterdam and Christchurch (New Zealand). In 2008, Margreet obtained a masters degree (cum laude) in Health Economics, Policy and Law from the Erasmus University in Rotterdam. Since this time she has been working as a researcher at the institute for Medical Technology Assessment of the institute of Health Policy and Management at the Erasmus University in Rotterdam. In 2014, Margreet obtained her PhD on drug reimbursement decision making. She has been involved in setting up several patient registries in oncology. Her research interests are in the field of health economics and include drug reimbursement policies and outcomes research using real-world data. She is currently involved in disease registries for melanoma, multiple myeloma, colon and lung cancer.

All publications (45)

Scholarly Publication (33)

H.M. Blommestein, M.G. Franken, C.H.Y. van Beurden-Tan, N.M.A. Blijlevens, P.C. Huijgens, P. Sonneveld, C.A. Uyl - de Groot & S. Zweegman (2021). Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. Jama Network Open, 4 (3). doi: 10.1001/jamanetworkopen.2021.3497

B. Leeneman, C.A. de Groot, M. Aarts, A.C.J. Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, J. de Groot, K.H. Herbschleb, J. van der Hoeven, G. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M. Wouters, J. Haanen & M.G. Franken (2020). Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers, 12 (4):1003. doi: 10.3390/cancers12041003

S.A. Blankenstein, M. Aarts, F. van den Berkmortel, M. Boers-Sonderen, A.J.M. Van den Eertwegh, M.G. Franken, J. Groot, J. Haanen, G. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M. Wouters & A.C.J. Akkooi (2020). Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. Cancers, 12 (5). doi: 10.3390/cancers12051176

B. Leeneman, M.G. Franken, V. Coupe, M.P. Hendriks, W.H.J. Kruit, P. Plaisier, S. van Ruth, J. Verstijnen, M. Wouters, H.M. Blommestein & C.A. de Uyl-de Groot (2019). Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. European Journal of Surgical Oncology, 45 (5), 825-831. doi: 10.1016/j.ejso.2019.01.225 [go to publisher's site]

M.G. Franken, B. Leeneman, M. Gheorghe, C.A. Uyl - de Groot, J. Haanen & P.H.M. van Baal (2019). A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 123, 58-71. doi: 10.1016/j.ejca.2019.08.032 [go to publisher's site]

M.G. Franken, I. Corro Ramos, J. Los & M.J. Al (2018). The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. BMC Family Practice, 19 (31). doi: 10.1186/s12875-018-0714-9 [go to publisher's site]

C.H.Y. van Beurden-Tan, M.G. Franken, H.M. Blommestein, C.A. de Uyl-de Groot & P. Sonneveld (2017). Reply to X. Armoiry et al. Journal of Clinical Oncology, 35 (25), 2976. doi: 10.1200/JCO.2017.73.7569

A. Jochems, M.G. Schouwenburg, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, H. Gelderblom, C.A. de Uyl-de Groot, M. Aarts, F. van den Berkmortel, W.A.M. Blokx, M.C. Cardous-Ubbink, G. Groenewegen, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters & J.J.M. van der Hoeven (2017). Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 72, 156-165. doi: 10.1016/j.ejca.2016.11.021

M.G. Franken, J.G. Gaultney, H.M. Blommestein, S.S. Tan, C.W.M. van Gils, P.C. Huijgens, P. Sonneveld, W.K. Redekop & C.A. de Uyl-de Groot (2012). Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma. (Extern rapport). Rotterdam: Erasmus Universiteit Rotterdam - GE-iMTA [go to publisher's site]

M. le Polain, M.G. Franken, M.A. Koopmanschap & I. Cleemput (2010). Drug reimbursement systems: international comparison and policy recommendations. (Extern rapport, KCE Reports, no 147C). Brussel: Federaal Kenniscentrum voor de gezondheidszorg - Centre fédéral d'expertise des soins de santé

Present position

(external) researcher

University

Erasmus University Rotterdam

School

Erasmus School of Health Policy & Management

Department

Health Technology Assessment (HTA)

Country

The Netherlands

Telephone

0104081372

# data[].attributes.attachment_link.description
(external) researcher Erasmus School of Health Policy & Management Health Technology Assessment (HTA) Margreet Franken, PhD is a senior researcher at the institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, The Netherlands. She obtained a Bachelor degree in Nursing (1992), after which she specialised in coronary (1995) and intensive care nursing (1998).

# data[].attributes.body
https://padlet.com/sabrinadietrich1/kw8ddbkoihe7qdbb

# data[].attributes.headline
Why this track is attractive from my perspective?

# data[].attributes.subject
Why this track is attractive from my perspective?

# data[].attributes.headline
Which job opportunities are we expecting as graduates from this track?

# data[].attributes.subject
Which job opportunities are we expecting as graduates from this track?

# data[].attributes.body
The Economic Evaluation track starts at the Erasmus University Rotterdam.

# data[].attributes.attachment_link.description
Erasmus University Rotterdam is a highly ranked, international research university, based in the dynamic and diverse city of Rotterdam, the Netherlands.

# data[].attributes.body
Technological advances, increasing wealth and population ageing have contributed to increasing demand for healthcare worldwide. Governments and healthcare organizations however have limited resources to meet these demands and therefore need to decide how to spend their budget in an optimal way.

The broad and diverse impacts of health problems on patients and society pose clear challenges for the evaluation of the costs and benefits of alternative intervention strategies to address these health problems. Yet, such information is of crucial importance for medical and policy decision-makers when deciding about optimal treatment and the funding of new interventions.

The specialisation in economic evaluation teaches these skills and equips students for working in the private and public sector. This involves knowledge of how to measure quality of life and costs, and to develop simulation models that allow estimation of the short- and long-term consequences of interventions as well as the uncertainty in these estimates

# data[].attributes.body
To make decisions about new pharmaceuticals and other medical innovations, it is necessary to evaluate their costs and benefits in a systematic manner:

How much should society be willing to spend to provide a new pharmaceutical that gives ten percent of the patients two more months to live?

Should costs due absence from work be included in the cost estimates?

What is an acceptable threshold for the costs per quality adjusted life year (QALY) for a very expensive orphan drug?

How can a modelling approach support decision in health care?

What is the impact of EU pharmaceutical legislation on the accessibility of drugs?

What are the key concepts of pharmaceutical pricing and market access?

# data[].attributes.body
... and continues at the University of Oslo.

# data[].attributes.attachment_link.description
The University of Oslo is a leading European university and Norway's largest. UiO is home to outstanding research and offers a great variety in study options.